FDA ALERTS

The U.S. Food and Drug Administration approved pralsetinib (Gavreto; Blueprint Medicines Corporation) for advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), according to a press release. The approval is for adult and pediatric patients ≥12 years old.

Read the full press release…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.